ATS 2024 Final Program

Click on the session title to view the speakers

192

MONDAY • MAY 20

12:31 Associate Editor Summary of Review Process and Paper Impact 12:36 TRPV4 Regulates the Macrophage Metabolic Response to Limit Sepsis-induced Lung Injury 12:53 Author - Editor Panel Discussion ATS RESEARCH PROGRAM; AM. LUNG ASSOCIATION; NHLBI, NINR, PCORI MID-DAY SESSION MD16 RESEARCH FUNDING OPPORTUNITIES 12:00 p.m. - 1:00 p.m. San Diego Convention Center Room 28A-B (Upper Level) Target Audience This session will benefit attendees with clinical, academic, research, and/or funding responsibilities. The information is appropriate for students as well as early-career, mid-career, and senior clinician scientists Objectives At the conclusion of this session, the participant will be able to: • describe the research priorities of each funding agency/organization represented on the panels • identify each presenting agency/organization’s available funding mechanisms and associated criteria • select an agency/organization and funding mechanism most appropriate for their research This session will introduce programs and research funding opportunities offered by multiple federal agencies and private organizations/foundations. Speakers will present current research priorities and mechanisms of funding available within their respective agency or organization. Time will also be provided for audience members to ask questions of the panel of speakers. 12:00 Introduction 12:02 National Heart Lung Blood Institute 12:10 American Lung Association 12:18 Patient Centered Outcomes Research Institute 12:26 ATS Research Program 12:34 National Institute of Nursing Research 12:42 Pulmonary Hypertension 12:50 Conclusion and Q&A

CTSA ONE HEALTH ALLIANCE MID-DAY SESSION

MD17 ASTHMA ACROSS SPECIES: A COMPARATIVE APPROACH TO

UNDERSTANDING PATHOLOGY AND THE MICROBIOTA

12:00 p.m. - 1:00 p.m.

San Diego Convention Center Room 29A-D (Upper Level)

Target Audience 1. Clinician-scientists treating asthma, seeking to learn from across disciplines. 2. Scientists interested in cross-species asthma models. 3. Clinicians and researchers interested in cross-species collaborations or interest in asthma microbiome. Objectives At the conclusion of this session, the participant will be able to: • improve awareness of two large animal models of allergic and severe asthma useful in human pre-clinical trials. Goal: to improve cross-species translational collaborations and enhance study of long-term remodeling effects of current asthma therapies. • understand respiratory dysbiosis associated with airway inflammation. Goal: to relate airway dysbiosis of animal models with human asthma and identify gaps in understanding that can be improved with animal models. • learn about changes in airway microbiome and inflammation of animals, and correlate these changes with large airway physiology that could improve understanding of human asthma. While asthma has benefitted from work in induced murine models, results may not translate well to human patients. Cats and horses spontaneously develop asthma similar to humans in anatomy, physiology, and immunology and may serve as important pre-clinical models. Cats develop allergic asthma with airway eosinophilia. Horses develop neutrophilic asthma. Asthma can be studied in pet cats or induced with clinically relevant aeroallergens in research cats. Asthma exacerbation and remission can be studied in horses by exposure to naturally offending antigens. Complex genetics, shared environmental exposures, and airway dysbiosis increase the relevance of these spontaneous asthma models for humans. Both animal models allow us to study unexplored issues of human asthma in a unique way and possibly yield novel therapeutics. 12:00 Heterogeneity of Asthma Immunology in Humans

ATS 2024 Conference Program • San Diego, CA